Glucostop (Metformin Hydrochloride)

Glucostop is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan.

• As monotherapy in patients who do not achieve glycemic control with diet and exercise alone.
• In combination with other oral antidiabetic agents such as sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors.
• As an adjunct to insulin therapy when additional glucose lowering is needed.
• For patients with overweight or obesity to aid modest weight stabilization.
• To improve insulin sensitivity in peripheral tissues.

The safety profile of Glucostop reflects the typical adverse events associated with metformin therapy.

Common

• Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea.
• Metallic taste in the mouth.
• Mild loss of appetite.
• Headache.

Serious

• Lactic acidosis, a rare but potentially life‑threatening condition.
• Severe hypoglycemia when combined with insulin or insulin secretagogues.
• Significant elevation of liver enzymes.
• Persistent vomiting leading to dehydration.

Healthcare providers should evaluate several precautionary factors before prescribing Glucostop to ensure safe use.

• Assess renal function; avoid use in patients with eGFR below 30 mL/min/1.73 m².
• Review hepatic status, as liver disease may increase risk of lactic acidosis.
• Monitor for signs of vitamin B12 deficiency with long‑term therapy.
• Use caution in elderly patients due to higher incidence of gastrointestinal side effects.
• Discontinue before any radiographic procedures that use iodinated contrast agents.
• Consider dose adjustment during acute illness or dehydration.

Glucostop can interact with other medicines, affecting its efficacy or safety.

Avoid

• Iodinated contrast agents used for imaging studies; they may precipitate renal impairment.
• Alcoholic beverages in excess, which can increase risk of lactic acidosis.

Use with caution

• Other antidiabetic drugs that cause hypoglycemia, such as sulfonylureas or insulin.
• Cimetidine, which may increase metformin plasma concentrations.
• Certain diuretics that affect renal clearance.
• Medications that may interfere with vitamin B12 absorption, like proton pump inhibitors.